日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth.

Navitoclax(一种 Bcl-2/xL 抑制剂)和 YM155(一种 Survivin 抑制剂)与卡铂联合使用,可有效抑制卵巢癌肿瘤生长

Kenny Hilary A, Ip Carman Ka Man, Kelliher Lucy, Samantaray Tejas, Kordylewicz Kasjusz, Hoffmann Rachael, Rauch Sarah, Malacrida Beatrice, Skingsley Sophie L P, Balkwill Frances R, Battistini Chiara, Cavallaro Ugo, Wiedemeyer Wolf R, Lengyel Ernst

Integration of cell-type resolved spatial proteomics and transcriptomics reveals novel mechanisms in early ovarian cancer.

细胞类型分辨的空间蛋白质组学和转录组学的整合揭示了早期卵巢癌的新机制

Metousis Andreas, Kenny Hilary A, Shimizu Aasa, Schweizer Lisa, Ben-Moshe Shani, Bilecz Agnes, Krishnan Rahul, Zhang Jingwen, Alcazar Isabel, Kelliher Lucy, Ravi Mallika, Samantaray Tejas, Richter Sabrina, Li Yan, Wang Jiying, Steigerwald Sophia, Theis Fabian J, Rosenberger Florian A, Nordmann Thierry M, Yamada S Diane, Lastra Ricardo, Mann Matthias, Lengyel Ernst